Navigation Links
Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
Date:5/20/2013

Geneva, Switzerland (PRWEB) May 20, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that the Company’s co-founder will present data on the Company’s core technology at the 2013 Cell Line Development & Engineering Conference, May 20 - 23 at the Hyatt Regency La Jolla at Aventine in La Jolla, California. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology and Faculty of Biology and Medicine at the University of Lausanne, will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression,” on Monday, May 20 at 2:30 PM as part of the Application, Integration and Characterization of 'Omics in Cell Line Development tract.

Additionally, a poster presentation with data from the recently launched SURE CHO-Mplus™ Library, “CHO Cell Library for the Selection of Improved Recombinant Therapeutic Protein Production,” is scheduled to be presented at the conference. The poster presentation will discuss new solutions that address a broad range of recombinant protein secretion issues.

Presentation Abstract:
Epigenetic regulatory DNA elements prevent silencing and increase transgene integration and transcription for high and stable therapeutic production. We have sequenced the genome and transcriptome of a CHO cell line and of derived producer cell clones, yielding information on the integration locus, transgene integrity and copy number. Information on possible mechanisms allowing vector genomic integration was also obtained, providing approaches to further optimize transgene integration and expression.

Poster Abstract:
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene, thus boosting the overall expression of a therapeutic protein drug in mammalian cells.

However, there are additional cellular bottlenecks, notably in the molecular machineries of the secretory pathways. Most importantly, mammalian cells have some limitations in their intrinsic capacity to manage high level of protein synthesis as well as folding recombinant proteins. These bottlenecks often lead to increased cellular stress and, therefore, low production rates.

Our specific approach involves CHO cell line engineering. We constructed a CHO-M library based upon the CHO-M genome and transcriptome and using unique proprietary transposon vectors harboring SGE DNA elements to compensate for rate-limiting factors. This CHO-Mplus library displays a diversity of greater than 1x107 auxiliary proteins involved in secretory pathway machineries and cellular metabolism.
We show that our CHO-Mplus library enabled the selection of a clonal cell line expressing 10 fold more product by comparison to standard approaches.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/therapeutic_protein_CHO/cell_line_development/prweb10750615.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Targeted therapeutics for colon cancer to be presented at AACR meeting
6. NYU Langone experts present research, clinical advances at neurosurgeons meeting
7. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
8. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
9. Presentation of 1-year IVAN and 2-year CATT study results
10. Kessler Foundation researchers present at first International Congress on Cognition in MS
11. Protein may represent a switch to turn off B cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using the ... can reconnect with America as it explores some of the best places to hike ... an inventive new place for a family vacation, and have discovered hiking. Many will ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017  The Corporate Whistleblower ... employees of sleep therapy clinics to call us ... therapy clinic is involved in a substantial scheme ... in hearing from an employee of a medical ... a kickback scheme to provide medical practice groups with ...
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
(Date:5/9/2017)... 9, 2017  Demonstrating its commitment to representing ... for the Pharmaceutical Research and Manufacturers of America ... companies will now have to meet new research ... eligible to join PhRMA. "By putting ... sending a clear message that being a member ...
Breaking Medicine Technology: